Nephrol Dial Transplant (2003) 18: 1159-1166
© 2003 European Renal Association-European Dialysis and Transplant Association
Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis
1 Department of Nephrology, Clinical Center Skopje, University of Skopje, Macedonia and 2 Department of Nephrology-Hypertension, University of Antwerp, Belgium
Background. During the last few years the spectrum of renal osteodystrophy (ROD) in dialysis patients has been studied thoroughly and the prevalence of the various types of ROD has changed considerably. Whereas until a decade ago most patients presented with secondary hyperparathyroidism (HPTH), adynamic bone (ABD) has become the most common lesion within the dialysis population over the last few years. Much less is known about the spectrum of ROD in end-stage renal failure (ESRF) patients not yet on dialysis.
Methods. Transiliac bone biopsies were taken in an unselected group of 84 ESRF patients (44 male, age 54±12 years) before enrolment in a dialysis programme. All patients were recruited within a time period of 10 months from various centres (n=18) in Macedonia. Calcium carbonate was the only prescribed medication in patients followed up by the outpatient clinic.
Results. HPTH was found in only 9% of the patients, whilst ABD appeared to be the most frequent renal bone disease as it was observed in 23% of the cases next to normal bone (38%). A relatively high number of patients (n=10; 12%) fulfilled the criteria of osteomalacia (OM). Mixed osteodystrophy (MX) was diagnosed in 18% of the subjects. There was no significant difference between groups in age, creatinine, or serum and bone strontium and aluminium levels. Patient characteristics associated with ABD included male gender and diabetes, whilst OM was associated with older age (>58 years).
Conclusions. In an unselected population of ESRF patients already, 62% of them have an abnormal bone histology. ABD is the most prevalent type of ROD in this population. In the absence of aluminium or strontium accumulation the relatively high prevalence of a low bone turnover as expressed by either normal bone or ABD and OM is striking.
Keywords: adynamic bone disease; ESRF; hyperparathyroidism; osteomalacia; predialysis; renal osteodystrophy
Correspondence and offprint requests to: Patrick C. D'Haese, PhD, Department of Nephrology, University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem, Belgium. Email: dhaese{at}uia.ua.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Gal-Moscovici and S. M. Sprague Role of Bone Biopsy in Stages 3 to 4 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S170 - S174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mathew, R. J. Lund, L. R. Chaudhary, T. Geurs, and K. A. Hruska Vitamin D Receptor Activators Can Protect against Vascular Calcification J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1509 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Brandenburg and J. Floege Adynamic bone disease--bone and beyond NDT Plus, June 1, 2008; 1(3): 135 - 147. [Full Text] [PDF]
|
|
|
|
|
|
P. Messa, F. Macario, M. Yaqoob, K. Bouman, J. Braun, B. von Albertini, H. Brink, F. Maduell, H. Graf, J. M. Frazao, et al. The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 36 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Chertow, L. B. Pupim, G. A. Block, R. Correa-Rotter, T. B. Drueke, J. Floege, W. G. Goodman, G. M. London, K. W. Mahaffey, S. M. Moe, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Spasovski, A. Sikole, S. Gelev, J. Masin-Spasovska, T. Freemont, I. Webster, M. Gill, C. Jones, M. E. De Broe, and P. C. D'Haese Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2217 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. D'Haese, F. Santacruz, M. E. De Broe, Y. Taur, F. Al-Tureihi, G. Wolf-Klein, and P. J. Meunier Postmenopausal Osteoporosis and Strontium Ranelate N. Engl. J. Med., May 6, 2004; 350(19): 2001 - 2003. [Full Text] [PDF]
|
|
|
|
 |
|
 R J A Sims, M J D Cassidy, and T Masud The increasing number of older patients with renal disease BMJ, August 30, 2003; 327(7413): 463 - 464. [Full Text] [PDF]
|
|